What Is Sermorelin? GHRH (1-29) Amide — Structure, Receptor Mechanism and Research Use

Sermorelin is the synthetic amidated fragment GHRH (1–29): the first 29 residues of the 44-residue human growth hormone-releasing hormone, capped with a C-terminal amide. Decades of endocrine research showed this fragment carries virtually all the receptor-binding information the whole hormone contains — and that truncation is the molecule's whole rationale. If residues 30 through 44 add nothing measurable to receptor activation, a 29-residue peptide becomes a less expensive, simpler-to-synthesise and chemically more manageable probe of the GHRH receptor than the full hormone.

Below: the origin of the sequence, how it acts at the pituitary, what has been published about it, and how the material is specified and handled in the laboratory. Sermorelin ships as a lyophilized powder.

Discovery and structure

Human GHRH was first isolated in 1982 from pancreatic tumours in acromegaly patients — a curious route to discovery, made feasible because those tumours secreted the hypothalamic hormone in quantities no hypothalamic tissue could supply. The peptide obtained was 44 residues long. Subsequent structure–activity studies showed that the first 29 residues keep full biological potency and that the N-terminal end is indispensable: deleting even the initial residue destroys activity.

Sermorelin is precisely that 29-residue fragment, with an amide in place of the free C-terminal carboxylate. Amidation is what separates it from a plain truncation: it eliminates a terminal negative charge and improves receptor binding, and it is one of the identity points to verify on a certificate. The sequence contains one methionine, at position 27 — the residue most prone to oxidation, and the reason methionine oxidation keeps recurring in stability discussions of GHRH analogues.

In structural terms, sermorelin sits in the secretin-glucagon superfamily with VIP, PACAP, secretin and glucagon. Each activates a class B G protein-coupled receptor through the same two-domain process: the peptide's C-terminal segment docks into the receptor's large extracellular domain, then the N-terminal residues enter the transmembrane core and initiate signalling. This is why removing residues at the C-terminus is far better tolerated than removing them at the N-terminus.

Mechanism of action

Sermorelin binds GHRH receptors on pituitary somatotrophs. Coupling to Gs raises cAMP and activates protein kinase A, which both increases transcription of the growth hormone gene and triggers release of stored hormone. Prolonged exposure is additionally linked in the literature with proliferation of somatotrophs.

What makes the GHRH receptor an attractive research target is that the hormone release it produces stays under physiological control. Somatostatin tone still opposes secretion and IGF-1 negative feedback remains operative, so a GHRH agonist amplifies an existing regulated rhythm instead of overriding it — in contrast to giving recombinant growth hormone, which circumvents the axis completely. In animal studies this appears as retained pulsatility, the very reason sermorelin features in work on hypothalamic-pituitary regulation.

Sermorelin is also quickly degraded. Dipeptidyl peptidase-4 cuts the peptide after alanine at position 2, and the plasma half-life reported is only minutes. For some experiments that is a drawback; for others an asset, since brief exposure windows are exactly what studying pulsatile rather than continuous receptor signalling requires. Analogues engineered to withstand this cleavage — modified GRF 1-29 with its substituted position 2, and tesamorelin with its N-terminal acyl group — exist for that reason.

Research applications

Pituitary and hypothalamic physiology

Its main use is as a reference GHRH receptor agonist in cell and animal experiments: receptor binding, cAMP accumulation, somatotroph responsiveness and characterisation of pulsatile secretion in intact animals. Here sermorelin serves as the standard, not as the object of study.

Diagnostic endocrinology

Sermorelin acetate was once sold as a prescription product in the United States for growth hormone stimulation testing and paediatric growth hormone deficiency. It left the US market in 2008 for commercial, not safety, reasons. Those clinical data relate to an approved medicine used under medical supervision, not to research-grade material.

Comparative structure–activity studies

Sermorelin is the benchmark against which stabilised GHRH analogues are assessed, which is why it recurs throughout the tesamorelin and modified GRF 1-29 literature. Direct comparisons appear in tesamorelin vs sermorelin and CJC-1295 versus sermorelin.

Combination pharmacology

A separate line of work pairs GHRH receptor agonists with ghrelin-receptor agonists such as ipamorelin, since both receptors sit on the same cell but use different second messengers — cAMP and phospholipase C respectively — and some models report their combined effect exceeding the sum of the parts. Pre-blended research material is available for this design.

Available formats and vial sizes

Sermorelin is supplied as lyophilized powder in sealed vials of 2 mg (€45), 5 mg (€75) and 10 mg (€120). At 3357.93 g/mol, a 5 mg vial holds about 1.49 micromoles — plenty for receptor pharmacology, which works in the nanomolar range, though animal studies exhaust it much faster. The GHRH family is listed under GHRH analogs, within the wider growth hormone and performance peptides category.

Reconstitution and storage at the bench

Worked example: a 5 mg vial reconstituted in 2 mL of bacteriostatic water gives 2.5 mg/mL (2,500 mcg/mL), and 0.1 mL — 10 units on a U-100 syringe — contains 250 mcg. Expressed as molarity, 2.5 mg/mL of a 3357.93 g/mol peptide is about 745 micromolar, so a receptor assay at 10 nanomolar needs roughly a 75,000-fold dilution, carried out in steps rather than in one jump.

Two stability considerations apply specifically to this peptide. Methionine 27 is oxidation-prone, so keep stock solutions away from air and light. And wherever active DPP-4 is present in a biological matrix, degradation starts immediately — a methodological issue rather than a storage one. Store lyophilized vials at −20 °C, protected from light and moisture, and aliquot reconstituted material and keep it cold. Details are in the reconstitution guide and the storage guide.

Purity and reading the certificate of analysis

Each lot is purified by reversed-phase HPLC to at least 99%, confirmed by mass and accompanied by a lot-matched certificate. Three checks count here. First, the C-terminal amide: the observed mass should agree with 3357.93 g/mol, and a figure roughly 1 Da higher signals the free acid instead. Second, oxidation: a +16 Da satellite on the mass spectrum, or an early-eluting shoulder in the chromatogram, indicates oxidised methionine at position 27. Third, deletion sequences: 29 residues is a moderately long synthesis, and a chain short by one residue can elute very close to the target, so chromatographic resolution matters as much as the stated percentage. Our COA reading guide applies these checks to real documents.

Regulatory position

Sermorelin acetate was an approved prescription product in the United States until its withdrawal in 2008; in some jurisdictions compounding pharmacies prepare sermorelin under prescription. Research-grade peptide is not a pharmaceutical product, carries none of the corresponding regulatory assurances, and is supplied for laboratory research only, not for human consumption.

Related compounds and further reading

In the GHRH family, modified GRF 1-29 is the stabilised short analogue, CJC-1295 with DAC the long-acting albumin-binding form, and tesamorelin the acylated full-length analogue. On the secretagogue side, ipamorelin, GHRP-2 and GHRP-6 act through a quite different receptor. The complete picture is set out in the GH secretagogue landscape explained.